Moreover, in resistant cell lines, the oxidative damage caused by gemcitabine could be resisted, while inhibition of Kras or MACC1-AS1 significantly increased the level of oxidative damage, and when MACC1-AS1 was simultaneously upregulated in pancreatic cancer cell lines, it enhanced their resistance to oxidative reactions. This evidence concerns the gene KRAS and pancreatic neoplasm.